Nilotinib 200mg Capsules

Generic Name: Not Available

Out of stock
Regular price Rs.0.00 PKR inc. VAT

You can promote by sharing on social networks on the links.

Product Description

Product Name: Nilotinib 200mg Capsules

Product Form: Capsules

Pack Size: 28's

Manufactured By: Novartis

Used For:

  • Chronic Myeloid Leukemia (CML): Nilotinib, also known as Tasigna, is used to treat chronic myeloid leukemia (CML) in patients who have the Philadelphia chromosome-positive (Ph+) and have not responded to, or are intolerant to, other treatments. It is typically used for:
    • Chronic Phase CML: For patients with chronic phase CML.
    • Accelerated or Blast Phase CML: For patients with accelerated or blast phase CML who are Philadelphia chromosome-positive.

Side Effects:

  • Nausea and Vomiting: Gastrointestinal symptoms including nausea and vomiting.
  • Fatigue: General feeling of tiredness or weakness.
  • Rash: Skin reactions such as rash or itching.
  • Elevated Liver Enzymes: Liver function abnormalities including elevated liver enzymes.
  • Headache: Common side effect experienced by some patients.
  • Peripheral Edema: Swelling of hands, feet, or legs.
  • Abdominal Pain: Pain or discomfort in the abdominal area.
  • Heart Issues: Risk of cardiovascular issues, including QT prolongation (a type of heart rhythm problem).

Precautions:

  • Liver Function Monitoring: Regular monitoring of liver function tests to detect potential liver-related issues.
  • Heart Health: Monitor for cardiovascular symptoms and potential QT prolongation. ECG monitoring may be required.
  • Drug Interactions: Inform your healthcare provider of all other medications and supplements you are taking, as Nilotinib can interact with various drugs.
  • Pregnancy and Breastfeeding: Not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant. Consult with your healthcare provider for advice.
  • Kidney Function: Use with caution in patients with impaired kidney function.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)